BioSpace News Archive

The Agreement with Chemi Pharma strengthens Revive’s ambition in becoming a leader in the medical cannabis market.

The FDA has granted TAGRISSO Priority Review status, and previously granted Breakthrough Therapy Designation for TAGRISSO in the 1st-line treatment of patients with metastatic EGFR mutation-positive (EGFRm) NSCLC.

The blunt tip catheter facilitates true lumen passage of lesions, both above and below the knee, in the peripheral vasculature.

The $800,000 grant will fund a clinical trial to determine if the use of stem cell therapy can improve outcomes for patients who suffer rotator cuff tears.

All of Respicardia’s existing major investors helped to complete the financing round.

Mr. Becker is a seasoned financial executive with more than 15 years of experience in the biotechnology industry.

Eisai announced that it has created educational materials for understanding dementia and thinking about what one can do for elementary and secondary school students, and has commenced marketing these materials primarily to local governments, educational institutions as well as medical and nursing care professionals from today.

To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors.

Aerpio announced today the grant of inducement equity awards to its newly appointed Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., and its newly appointed Chief Financial Officer, Michael Rogers.

BIOTECanada welcomes today’s announcement by the federal government to commit $400 million to the federal Venture Capital Catalyst Initiative (VCCI).